The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

  • Andreas Heres Diddens (Contributor)
  • Sophie Kraaijenga (Creator)
  • Veerle Coupé (Creator)
  • Frans Hilgers (Netherlands Cancer Institute, University of Amsterdam) (Creator)
  • Lisette van der Molen (Contributor)
  • L.E. Smeele (Contributor)
  • Valesca Retèl (Creator)
  • Lisette van der Molen (Creator)

Dataset

Description

Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than...
Date made available2016
PublisherTaylor & Francis

Cite this